Cancer Dynamics
DOI:
https://doi.org/10.17140/CSMMOJ-6-130Abstract
Even though cancer researchers nowadays are trying to develop many key cellular pathways susceptible to be tackled by therapeutic
approaches, we are far from being able to consider some cancers as curable diseases in general terms. From a pharmacodynamic
point of view, the main potential molecular targets involved are driver oncogenes, tumor suppressor genes, growth factors and their receptors, transcription factors, tyrosine kinases, and cell adhesion molecules. If we consider possible targets at higher organization levels, we can intervene in aspects such as chromatin organization, tumor microenvironment, angiogenesis, apoptosis, senescence, mitochondria metabolism, and immune pathways.
References
Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, et al. The evolutionary history of 2.658 cancers. Nature. 2020; 578: 122-128. doi: 10.1038/s41586-019-1907-7
Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging Ras back in the ring. Cancer Cell. 2014; 25: 272-281. doi: 10.1016/j. ccr.2014.02.017
Herbst R, SchlessingerJ. ‘Undruggable’ cancer protein targeted. Nature. 2019; 575: 294-295.
Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinosi-Opinion | Volume 6 | Number 1| Gandia D et al tol-3-kinase growth disorders and cancer. N Engl J Med. 2018; 379(21): 2052-2062. doi: 10.1056/NEJMra1704560
Muller P, Vousden K. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 2014; 25: 304-317. doi: 10.1016/j.ccr.2014.01.021
Hayes DF. HER2 and breast cancer: A phenomenal success story. N Engl J Med. 2019; 381(13): 1284-1286. doi: 10.1056/ NEJMcibr1909386
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. The Lancet. 2019; 394: 1467-1480. doi: 10.1016/ S0140-6736(19)32319-0
Chow LQM. Head and neck cancer. N Engl J Med. 2020; 382(1): 60-72. doi: 10.1056/NEJMra1715715
Claudiani S, Apperley J. The argument for using imatinib in CML. Hematology Am Soc Hematol Educ Program. 2018; 2018(1): 161-167. doi: 10.1182/asheducation-2018.1.161
Bedard P, Hyman D, Davids M, Siu L. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020; 395: 1078-1088. doi: 10.1016/S0140-6736(20)30164-1
Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018; 8(1): 24-36. doi: 10.1158/2159- 8290.CD-17-0605
Mei M, Aldoss I, Marcucci G, Pullarkat V. Hypomethylating agents in combination with Venetoclax for acute myeloid leuke-mia: Update on clinical trial data and practical considerations for use. Am J Hematol. 2019; 94(3): 358-362. doi: 10.1002/ajh.25369
Hanahan D, Weinberg R. Hallmarks of cancer: The next gen-eration. Cell. 2011; 144: 646-674. doi: 10.1016/j.cell.2011.02.013
Qiao Y, Dsouza C, Matthews AA, Jin Y, He W, Bao J, et al. Discovery of small molecules targeting GRP78 for antiangiogen-ic and anticancer therapy. Eur J Med Chem. 2020; 193: 112228. doi: 10.1016/j.ejmech.2020.112228
Teti G, Biondo C, Beninati C. The phagocyte, Metchnikoff, and the foundation of immunology. Microbiol Spectr. 2016; 4(2). doi: 10.1128/microbiolspec.MCHD-0009-2015
Ribas A, Wolchok J. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382): 1350-1355. doi: 10.1126/sci-ence.aar4060
Allison JP, Honjo T. Press release: The Nobel Prize in Physi-ology or Medicine 2018. nobelprize Web site. https://www.no-belprize.org/prizes/medicine/2018/press-release/. Accessed March 22, 2020.
Rosemberg S, Lotze M, Muul L, Chang A, Avis F, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316(15): 889- 97. doi: 10.1056/NEJM198704093161501
Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Gan-guly N. CAR T-cell therapy: A new era for cancer treatment. Oncol Rep. 2019; 42(6): 2183-2195. doi: 10.3892/or.2019.7335
Korolev K, Xavier J, Gore J. Turning ecology and evolution against cancer. Nat Rev Cancer. 2014; 14: 371-380. doi: 10.1038/ nrc3712 Submit your article to this journal | https://openventio.org/submit-manuscript/ 4 Gandia D et al
Powell K. Survival of the fittest cells. Nature. 2019; 574: 310- 312. doi: 10.1096/fj.08-108985
Muppalla J, Muddana K, Dorankula S, Thokala M, Pasupula A. Microenvironment: A role in tumour progression and prog-nosis. J Clin Diagn Res. 2013; 7(9): 2096-2099. doi: 10.7860/ JCDR/2013/6619.3419
Luo G, Liu N. An integrative theory for cancer. Int J Mol Med. 2019; 43: 647-656. doi: 10.3892/ijmm.2018.4004
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
